Abstract: An adrenaline pharmaceutical solution including at least: adrenaline or a pharmaceutically-acceptable salt thereof; vitamin E TPGS; a chelating agent; a solvent. The method also relates to its use in the treatment of anaphylactic shocks, cardiac arrests, asthma and cardiocirculatory distresses. The method also concerns an injection kit including an injection device and this pharmaceutical solution.

Abstract: An adrenaline pharmaceutical solution including at least: adrenaline or a pharmaceutically-acceptable salt thereof; vitamin E TPGS; a chelating agent; a solvent. The method also relates to its use in the treatment of anaphylactic shocks, cardiac arrests, asthma and cardiocirculatory distresses. The method also concerns an injection kit including an injection device and this pharmaceutical solution.

Abstract: A miniature valve for filling the reservoir of an apparatus for the transdermal administration of a medicine including a) a substrate, b) a fuel charge arranged on the substrate opposite the passage to be opened through it, and c) an electric resistor placed in contact with the fuel charge so that the supply of this resistor with a predetermined electric energy ensures the combustion of the charge and the opening of the passage by local rupture of the substrate under the pressure of the fuel gases of the charge. The device is useful for filling a medicine reservoir for the transdermal administration medicine aided by inophoresis.

Abstract: A novel transdermal matrix system for the percutaneous delivery of a hormone, including a carrier and an adhesive matrix, is disclosed. The matrix includes (a) 39-61 parts by weight of an ethylene/vinyl acetate copolymer, (b) 12-17 parts by weight of 2-octyldodecyl myristate, (c) 5-17 parts by weight of diethyl phthalate, (d) 10-16 parts by weight of a compound selected from N-alkyl-2-pyrrolidones, wherein the alkyl group is a C.sub.4-15 group, and (e) 1-12 parts by weight of at least one hormone selected from the group consisting of oestrogenic and progestogenic components. A method for preparing said transdermal matrix system and the therapeutical use of said system are also disclosed.

Abstract: The device comprises a reservoir (3) containing an active principle in ionized form, first (1) and second (2) electrodes in contact with a face of the reservoir (3) and the skin (6) of the patient, respectively, the other face of the reservoir being applied to the skin (6) of the patient and means (5) for circulating selectively an electric current between said electrodes in order to help the passage of a flow of active principle under the patient's skin. The device further comprises a) a control grid (11) arranged on the face of the reservoir (3) which is intended to be applied to the skin (6) of the patient and b) control means (10), (9), (13) for cutting off the assistance current during a predetermined period of time and to circulate a reverse current between the grid (11) and the first electrode (1) which is intended to cancel substantially the passive flow of ions of the active principle which would otherwise pass under the patient's skin.

Abstract: The present invention relates to a new self-adhesive transdermal matrix system for the administration of a hormone by percutaneous route, said system which comprises a support and self-adhesive matrix, having a matrix comprising:(a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer,(b) 5 to 20 parts by weight of a cellulosic material,(c) 35 to 55 parts by weight of at least one compound selected from the group consisting of: crotamiton, N-substituted 2-pyrrolidones of the formula I, ##STR1## in which the R group represents a (C.sub.1 -C.sub.15)-alkyl, cyclohexyl or 2-hydroxyethyl group, and higher C.sub.12 -C.sub.20 aliphatic alcohols, and(d) 0,01 to 7 parts by weight of a hormone selected from the group consisting of estrogen components, progestogen components and mixtures thereof.It also relates to a method for preparing this transdermal matrix system.

Abstract: The device comprises a switched-mode power supply (1) equipped with an electronic switching member (T.sub.1), the closing of which controls the power supply to an inductor (L.sub.1) which discharges, when the member reopens, into a capacitor (C.sub.1) at the terminals of which the output voltage of the device appears, characterized in that it comprises (a) storage means for recording a sequence of image numbers of successive segments of the predetermined waveform, (b) a clocked digital counter (2) and (c) means (3) for successively loading this counter (2) with each of the numbers of this sequence considered as a bound of the count performed by the counter (2), the latter cyclically controlling the closing of the switching member (T.sub.1) for a predetermined time interval, each time the count performed reaches the limit thus fixed.

Abstract: The device comprises a switched-mode power supply (1) equipped with an electronic switching member (T.sub.1), the closing of which controls the power supply to an inductor (L.sub.1) which discharges, when the member reopens, into a capacitor (C.sub.1) at the terminals of which the output voltage of the device appears, characterized in that it comprises (a) storage means for recording a sequence of image numbers of successive segments of the predetermined waveform, (b) a clocked digital counter (2) and (c) means (3) for successively loading this counter (2) with each of the numbers of this sequence considered as a bound of the count performed by the counter (2), the latter cyclically controlling the closing of the switching member (T.sub.1) for a predetermined time interval, each time the count performed reaches the limit thus fixed.

Abstract: The present invention relates to a novel dosage form of fenofibrate containing fenofibrate and a solid surfactant which have been co-micronized.It also relates to the method for the preparation of this dosage form and its use for improving the bioavailabity in vivo.

Abstract: The present invention relates to a novel self-adhesive matrix for the percutaneous administration of an active ingredient. This matrix comprises a combination of the following:(a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer material,(b) 40 to 60 parts by weight of a higher aliphatic monoalcohol compound,(c) 1 to 20 parts by weight of a cellulose derivative material,(d) 0.1 to 8 parts by weight of a polyhydric alcohol compound, and(e) 0.01 to 10 parts by weight of an active ingredient which can be administered percutaneously,the weight ratio a+c/b+d being between 0.7 and 1.3.

Abstract: The present invention relates to a novel self-adhesive matrix for the percutaneous administration of a pharmaceutical active ingredient. This matrix comprises a combination of the following:(a) 30 to 50 parts by weight of an ethylene/vinyl acetate copolymer material,(b) 20 to 45 parts by weight of a higher aliphatic monoalcohol compound,(c) 5 to 20 parts by weight of a cellulose derivative material,(d) 1 to 20 parts by weight of an ester compound of a polyhydric alcohol with a fatty aliphatic acid, and(e) 0.1 to 20 parts by weight of an active ingredient which can be administered percutaneously.